ScoreWhy is Newron Pharmaceuticals SpA ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 231.49%
- Poor long term growth as Net Sales has grown by an annual rate of 48.06% and Operating profit at 29.66% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 1624.07%, it has a Very Expensive valuation with a 190.40 Price to Book Value
- Over the past year, while the stock has generated a return of 83.42%, its profits have risen by 236.2% ; the PEG ratio of the company is 0.1
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Newron Pharmaceuticals SpA for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Newron Pharmaceuticals SpA
83.42%
0.96
62.66%
Switzerland SMI
1.42%
-0.08
16.69%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
48.06%
EBIT Growth (5y)
29.66%
EBIT to Interest (avg)
-2.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
27.41
Sales to Capital Employed (avg)
0.41
Tax Ratio
26.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.64%
ROE (avg)
231.49%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
190.40
EV to EBIT
8.72
EV to EBITDA
8.67
EV to Capital Employed
29.98
EV to Sales
5.13
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
343.88%
ROE (Latest)
1624.07%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CHF 10.59 MM
NET SALES(Q)
At CHF 11.2 MM has Grown at 241.99%
CASH AND EQV(HY)
Highest at CHF 40.36 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 6.53 times
PRE-TAX PROFIT(Q)
At CHF -0.57 MM has Grown at 93.5%
NET PROFIT(Q)
At CHF -0.58 MM has Grown at 93.34%
-1What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 101.03% (YoY
Here's what is working for Newron Pharmaceuticals SpA
Net Sales
At CHF 11.2 MM has Grown at 241.99%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (CHF MM)
Operating Cash Flow
Highest at CHF 10.59 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CHF MM)
Pre-Tax Profit
At CHF -0.57 MM has Grown at 93.5%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CHF MM)
Net Profit
At CHF -0.58 MM has Grown at 93.34%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CHF MM)
Cash and Eqv
Highest at CHF 40.36 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 6.53 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Newron Pharmaceuticals SpA
Raw Material Cost
Grown by 101.03% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
